Legochem Biosciences, Inc.

Intocell, Inc.

Legochem Bioscience Ltd.

The Green Cross Corporation

Neopharm Co., Ltd.

Y-Biologics Inc.

Sung Ho Woo

Hyang Sook Lee

Tae Kyo Park

Yong Zu Kim

Young Lag Cho

Ho Young Song

Sang Eun Chae

Sung Yoon Baek

Sun Young Kim

Sunyoung Kim

Jaeho Lee

Taekyo Park

Jongun Cho

Kyu Man Oh

Doohwan Jung

Donghoon Seo

Sangkwang Lee

Sanghyeon Yun

Okku Park

Beomseok Seo

Jong Un Cho

Suho Park

Doo Hwan Jung

Jeiwook Chae

Yeong Soo Oh

Chul-Woong Chung

Yun Hee Park

Dae Yon Lee

Jeong Hee Ryu

Ji Young Min

Sena Kim

Minah Seol

Jeon Yang

Ju Hyun Park

Joung Yul Yun

Yeon Ok Kim

Suk Ho Lee

Chul Soon Park

Seong Jin Kim

Hye Jin Heo

Hong Bum Lee

Hyun Jin Kwon

Dae Hyuck Kang

Sang Hui Jo

Young Jae Yang

Young Woo Park

Jinhwa Lee

Soongyu Choi

Sang Kwang Lee

Se Kyoo Jeong

Jae Eun Park

Hye Jin Kang

Jeong Eun Jeon

Byeong Deog Park

Hyun Ju Lee

Hyun Mi Lee

Youngja Song

Kyuman Oh

Jungsub Choi

Beom Seok Seo

Yoo Hoon Kim

Ji Yeon Lim

Uk Il Kim

Dong Hoon Seo

Hee Sock Park

Jae Yeon Kim

Yosup Rew

Jina Song

Jihyeon Ha

Eun-Young Shim

Yunjung Ko

Eunjin Lee

So-Hyun Yoon

Minju Lee

Hyung Sub Gwak

Young Zu Kim

Jae Ho Lee

Hyung Mook Choi

Su Ho Park

Provided are a compound including a cleavable linker, a use thereof, and an intermediate compound for preparing the same, and more particularly, the compound including a cleavable linker of the present invention may include an active agent (for example, a drug, a toxin, a ligand, a probe for detection, etc.) having a specific function or activity, a SOfunctional group which is capable of selectively releasing the active agent, and a functional group which triggers a chemical reaction, a physicochemical reaction and/or a biological reaction by external stimulation, and may further include a ligand (for example, oligopeptide, polypeptide, antibody, etc.) having binding specificity for a desired target receptor.

Compounds comprising cleavable linker and uses thereof

The present disclosure provides compounds and compositions comprising substituted benzodiazepines of the class of Formula I:

Substituted benzodiazepines as antibody-drug conjugates

The present disclosure relates to antibody-drug conjugates (ADCs) wherein one or more active agents are conjugated to an anti-B7-H3 antibody through a linker. The linker may comprise a unit that covalently links active agents to the antibody. The disclosure further relates to monoclonal antibodies and antigen binding fragments, variants, multimeric versions, or bispecifics thereof that specifically bind B7-H3, as well as methods of making and using these anti-B7-H3 antibodies and antigen-binding fragments thereof in a variety of therapeutic, diagnostic and prophylactic indications.

Antibody-drug conjugates comprising anti-B7-H3 antibodies

The present disclosure provides compounds and compositions capable of extending lifespan, and methods of use thereof.

Benzodiazepine derivatives and uses thereof

The present invention relates to a compound bearing a self-immolative linker having &#x3b2;-galactoside-introduced thereto. In a compound bearing a &#x3b2;-galactoside-introduced self-immolative linker according to the present invention, particularly, the self-immolative linker may form a glycosidic bond with a protein (e.g., an oligopeptide, polypeptide, an antibody, etc.) or ligand which has specific affinity for a desired target or with an active agent (e.g., a drug, a toxin, a ligand, a detection probe, etc.), which has a specific function or activity so as to allow the selective release of the active agent within a target cell.

Compound bearing beta-galactoside-introduced self-immolative linker

Provided herein are compounds comprising a self-immolative group, and the compounds comprising a self-immolative group according to the present invention may include a protein (for example, an oligopeptide, a polypeptide, an antibody, or the like) having substrate-specificity for a target and an active agent (for example, a drug, a toxin, a ligand, a detection probe, or the like) having a specific function or activity.

Compounds comprising self-immolative group

Provided are compounds comprising a self-immolative group, and the compounds comprising a self-immolative group according to the present invention may include a protein (for example, an oligopeptide, a polypeptide, an antibody, or the like) having substrate-specificity for a target and an active agent (for example, a drug, a toxin, a ligand, a detection probe, or the like) having a specific function or activity.

Provided are methods of use of compounds comprising a self-immolative group, which compounds may include a protein (for example, an oligopeptide, a polypeptide, an antibody, or the like) having substrate-specificity for a target and an active agent (for example, a drug, a toxin, a ligand, a detection probe, or the like) having a specific function or activity.

The present invention relates to a novel crystalline form of 5-chloro-N-({(5S)-2-oxo-3-[4-(5,6-dihydro-4H-[1,2,4]triazin-1-yl)phenyl]-1,3-oxazolidin-5-yl}methyl)thiophene-2-carboxamide methanesulfonate and a pharmaceutical composition containing the same. The novel crystalline form of a compound according to the present invention exhibits excellent stability even in high-temperature and humidity environments, and thus can be favorably used to prevent or treat diseases, such as thrombosis, myocardial infarction, atherosclerosis, inflammation, stroke, angina pectoris, restenosis after angioplasty, and thromboembolism.

Crystalline form of 5-chloro-N-({(5S)-2-oxo-3-[4-(5,6-dihydro-4H-[1,2,4]triazin-1-yl)phenyl]-1,3-oxazolidin-5-yl}methyl)thiophene-2-carboxamide methanesulfonate and pharmaceutical composition comprising same

The present invention relates to novel cephalosporin derivatives represented by X, Y, L, R1, and R2 are as same as defined in the description of the invention. The present invention also relates to pharmaceutical antibiotic compositions comprising a novel celphalosporin derivative represented by Chemical Formula 1, a prodrug thereof, a hydrate thereof, a solvate thereof, an isomer thereof, or a pharmaceutically acceptable salt thereof as an effective ingredient. According to the present invention, novel cephalosporin derivatives, a prodrug thereof, a hydrate thereof, a solvate thereof, an isomer thereof, or a pharmaceutically acceptable salt thereof as an effective ingredient for the broad spectrum of antibiotic resistant, low toxicity, particularly in Gram-negative bacteria, which can be useful with strong antimicrobial activity.

Cephalosporin derivatives and pharmaceutical compositions thereof

Disclosed is a novel oxazolidinone derivative represented by Formula 1 above, in particular, a novel oxazolidinone compound having a cyclic amidoxime or cyclic amidrazone group. In Formula 1, R and Q are the same as defined in the detailed description. In addition, disclosed is a pharmaceutical composition for an antibiotic which includes the novel oxazolidinone derivative of Formula 1, a prodrug thereof, a hydrate thereof, a solvate thereof, an isomer thereof, or a pharmaceutically acceptable salt thereof as an active ingredient. The novel oxazolidinone derivative, the prodrug thereof, the hydrate thereof, the solvate thereof, the isomer thereof, and the pharmaceutically acceptable salt thereof have broad antibacterial spectrum against resistant bacteria, low toxicity and strong antibacterial effects against Gram-positive and Gram-negative bacteria and thus may be effectively used as antibiotics.

Oxazolidinone derivative and medical composition containing same

Provided are heterocyclic compounds, having effects of treating and preventing inflammatory diseases and treating skin wounds, and particularly, exhibiting effects of recovering disrupted skin barriers, mitigating inflammation, and pruritus. Also, a composition containing the compound as an effective component can be used to mitigate various inflammatory diseases and protease activated receptor-2 (PAR-2)-overexpressed diseases, and can be particularly used as a composition having an anti-inflammatory function in inflammatory skin diseases including atopic dermatitis and the like, by inhibiting PAR-2 activity.

Heterocyclic compound, and composition for treating inflammatory diseases using same

Growing community of inventors

Daejeon, South Korea

Sung Ho Woo